ACTRN12619001421123已完成未知
Enhancing Type 2 Diabetes Risk Communication with Message Framing and Tailored Risk Feedback: An Online Randomised Controlled Trial
niversity of Wollongong0 个研究点目标入组 347 人开始时间: 2019年10月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 347
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •(1) Currently not diagnosed with diabetes,
- •(2) Score at least an intermediate (<5 points) on the AUSDRISK, and
- •(3) only Australian and American (i.e USA) participants,
排除标准
- •(1) Currently diagnosed with diabetes,
- •(2) Score low (4 points and below) on the AUSDRISK, and
- •(3) non-Australian and American (i.e USA) participants,
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 19.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-NLBristol-Myers Squibb International Corporation80
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-DEBristol-Myers Squibb International Corporation72
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO80
进行中（未招募）
1 期
A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)MedDRA version: 19.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002347-41-ESBristol-Myers Squibb International Corporation80
招募中
2 期
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.10025319Hodgkin LymphomaLymphomaNL-OMON53072Bristol-Myers Squibb4